Autolus Therapeutics plc
AUTLDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
4wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How AUTL's past catalysts played out
AUTO1
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
AUTO3 (CD19/22 CAR T cells
B Acute Lymphoblastic Leukemia
AUTO4
T Cell Non-Hodgkin Lymphoma
Obecabtagene autoleucel
Lupus Nephritis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AUTO1 | Phase 2 | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | - | - |
AUTO3 (CD19/22 CAR T cells | Phase 2 | B Acute Lymphoblastic Leukemia | - | - |
AUTO4 | Phase 2 | T Cell Non-Hodgkin Lymphoma | - | - |
Obecabtagene autoleucel | Phase 2 | Lupus Nephritis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Autolus Therapeutics plc's drug pipeline?→
CatalystAlert tracks 4 drug candidates in Autolus Therapeutics plc's (AUTL) pipeline across Phase 2. Its lead program is AUTO1 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Autolus Therapeutics plc's next FDA catalyst?→
Autolus Therapeutics plc's (AUTL) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AUTL biotech catalysts?→
Add AUTL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Autolus Therapeutics plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.